-
Product Insights
NewNet Present Value Model: HilleVax Inc’s HIL-214
Empower your strategies with our Net Present Value Model: HilleVax Inc's HIL-214 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: GSK plc’s Cobolimab
Empower your strategies with our Net Present Value Model: GSK plc's Cobolimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Gastroenteritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Gastroenteritis - Drugs In Development, 2023’, provides an overview of the Gastroenteritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gastroenteritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KB-001 in Dementia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. KB-001 in Dementia Drug Details: KB-001 is under development for the treatment of Alzheimer's disease,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HIL-214 in Gastroenteritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HIL-214 in Gastroenteritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.HIL-214 in GastroenteritisDrug Details:HIL-214 was under development for the prevention of acute gastroenteritis caused...
-
Product Insights
Net Present Value Model: HIL-214
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model HIL-214 Drug Details HIL-214 was under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – HIL-214
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry HIL-214 Drug Details HIL-214 was under development for the prevention of acute gastroenteritis caused...